New Cellgorithm™ data presented at ISSCR symposium indicates faster, scalable cell programming and add to Syntax Bio’s compounding proprietary data Company completes pancreatic beta cell screening milestones for lead program and enters process development with continued funding from Breakthrough T1D CHICAGO–(BUSINESS WIRE)–Syntax Bio, a synthetic biology company programming next generation regenerative medicines, today presented new …
Continue reading “Syntax Bio Programs Stem Cells Toward Pancreatic Beta Cells in Four Days”